S&P 500   3,281.68 (+1.17%)
DOW   28,785.95 (+0.88%)
QQQ   221.54 (+1.58%)
AAPL   316.75 (+2.52%)
FB   218.21 (+1.55%)
MSFT   165.53 (+2.00%)
GOOGL   1,454.00 (+1.56%)
AMZN   1,851.20 (+1.25%)
CGC   23.07 (+7.00%)
NVDA   247.23 (+2.93%)
BABA   210.26 (+2.33%)
MU   56.46 (+1.89%)
GE   11.69 (+2.19%)
TSLA   564.60 (+1.18%)
AMD   50.51 (+2.54%)
T   38.75 (+1.31%)
ACB   1.94 (+2.65%)
F   8.96 (+0.67%)
NFLX   350.27 (+2.16%)
BAC   33.42 (+1.74%)
DIS   137.85 (+1.43%)
S&P 500   3,281.68 (+1.17%)
DOW   28,785.95 (+0.88%)
QQQ   221.54 (+1.58%)
AAPL   316.75 (+2.52%)
FB   218.21 (+1.55%)
MSFT   165.53 (+2.00%)
GOOGL   1,454.00 (+1.56%)
AMZN   1,851.20 (+1.25%)
CGC   23.07 (+7.00%)
NVDA   247.23 (+2.93%)
BABA   210.26 (+2.33%)
MU   56.46 (+1.89%)
GE   11.69 (+2.19%)
TSLA   564.60 (+1.18%)
AMD   50.51 (+2.54%)
T   38.75 (+1.31%)
ACB   1.94 (+2.65%)
F   8.96 (+0.67%)
NFLX   350.27 (+2.16%)
BAC   33.42 (+1.74%)
DIS   137.85 (+1.43%)
S&P 500   3,281.68 (+1.17%)
DOW   28,785.95 (+0.88%)
QQQ   221.54 (+1.58%)
AAPL   316.75 (+2.52%)
FB   218.21 (+1.55%)
MSFT   165.53 (+2.00%)
GOOGL   1,454.00 (+1.56%)
AMZN   1,851.20 (+1.25%)
CGC   23.07 (+7.00%)
NVDA   247.23 (+2.93%)
BABA   210.26 (+2.33%)
MU   56.46 (+1.89%)
GE   11.69 (+2.19%)
TSLA   564.60 (+1.18%)
AMD   50.51 (+2.54%)
T   38.75 (+1.31%)
ACB   1.94 (+2.65%)
F   8.96 (+0.67%)
NFLX   350.27 (+2.16%)
BAC   33.42 (+1.74%)
DIS   137.85 (+1.43%)
S&P 500   3,281.68 (+1.17%)
DOW   28,785.95 (+0.88%)
QQQ   221.54 (+1.58%)
AAPL   316.75 (+2.52%)
FB   218.21 (+1.55%)
MSFT   165.53 (+2.00%)
GOOGL   1,454.00 (+1.56%)
AMZN   1,851.20 (+1.25%)
CGC   23.07 (+7.00%)
NVDA   247.23 (+2.93%)
BABA   210.26 (+2.33%)
MU   56.46 (+1.89%)
GE   11.69 (+2.19%)
TSLA   564.60 (+1.18%)
AMD   50.51 (+2.54%)
T   38.75 (+1.31%)
ACB   1.94 (+2.65%)
F   8.96 (+0.67%)
NFLX   350.27 (+2.16%)
BAC   33.42 (+1.74%)
DIS   137.85 (+1.43%)
Log in

NASDAQ:PTCT - PTC Therapeutics Stock Price, Forecast & News

$50.75
-0.34 (-0.67 %)
(As of 01/28/2020 12:26 PM ET)
Today's Range
$50.66
Now: $50.75
$52.44
50-Day Range
$47.55
MA: $50.00
$53.80
52-Week Range
$27.53
Now: $50.75
$54.37
Volume16,527 shs
Average Volume646,234 shs
Market Capitalization$3.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.91
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTCT
CUSIPN/A
Phone908-222-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$264.73 million
Book Value$6.12 per share

Profitability

Net Income$-128,080,000.00

Miscellaneous

Employees511
Market Cap$3.13 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive PTCT News and Ratings via Email

Sign-up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.


PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its quarterly earnings results on Tuesday, October, 29th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the Zacks' consensus estimate of ($0.91) by $0.15. The biopharmaceutical company had revenue of $71.40 million for the quarter, compared to the consensus estimate of $72.03 million. PTC Therapeutics had a negative net margin of 74.86% and a negative return on equity of 31.92%. The business's revenue was up 33.2% compared to the same quarter last year. During the same period last year, the company posted ($1.06) EPS. View PTC Therapeutics' Earnings History.

When is PTC Therapeutics' next earnings date?

PTC Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for PTC Therapeutics.

What guidance has PTC Therapeutics issued on next quarter's earnings?

PTC Therapeutics updated its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $306-306 million, compared to the consensus revenue estimate of $302.78 million.

What price target have analysts set for PTCT?

10 brokers have issued 12-month price objectives for PTC Therapeutics' stock. Their forecasts range from $43.00 to $81.00. On average, they expect PTC Therapeutics' stock price to reach $59.13 in the next twelve months. This suggests a possible upside of 15.7% from the stock's current price. View Analyst Price Targets for PTC Therapeutics.

What is the consensus analysts' recommendation for PTC Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PTC Therapeutics.

Has PTC Therapeutics been receiving favorable news coverage?

Media coverage about PTCT stock has been trending very negative on Tuesday, InfoTrie reports. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PTC Therapeutics earned a daily sentiment score of -3.8 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for PTC Therapeutics.

Who are some of PTC Therapeutics' key competitors?

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals PLC- (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Regulus Therapeutics (RGLS), Cisco Systems (CSCO), Aduro BioTech (ADRO) and Gilead Sciences (GILD).

Who are PTC Therapeutics' key executives?

PTC Therapeutics' management team includes the folowing people:
  • Dr. Stuart W. Peltz, Co-Founder, CEO & Exec. Director (Age 59)
  • Dr. Allan Steven Jacobson, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 73)
  • Ms. Christine Utter, Principal Financial Officer & Treasurer (Age 41)
  • Mr. Marcio Souza, Chief Operating Officer (Age 40)
  • Dr. Neil Almstead, Chief Technical Operations Officer (Age 52)

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.98%), California Public Employees Retirement System (0.29%), Assenagon Asset Management S.A. (0.17%), Dupont Capital Management Corp (0.04%) and Exane Derivatives (0.00%). Company insiders that own PTC Therapeutics stock include Christine Marie Utter, Emily Luisa Hill, Marcio Souza, Mark Elliott Boulding, Michael Schmertzler, Neil Gregory Almstead and Stuart Walter Peltz. View Institutional Ownership Trends for PTC Therapeutics.

Which major investors are selling PTC Therapeutics stock?

PTCT stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A.. Company insiders that have sold PTC Therapeutics company stock in the last year include Christine Marie Utter, Emily Luisa Hill, Marcio Souza, Mark Elliott Boulding, Neil Gregory Almstead and Stuart Walter Peltz. View Insider Buying and Selling for PTC Therapeutics.

Which major investors are buying PTC Therapeutics stock?

PTCT stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., California Public Employees Retirement System, Dupont Capital Management Corp and Exane Derivatives. View Insider Buying and Selling for PTC Therapeutics.

How do I buy shares of PTC Therapeutics?

Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $51.10.

How big of a company is PTC Therapeutics?

PTC Therapeutics has a market capitalization of $3.15 billion and generates $264.73 million in revenue each year. The biopharmaceutical company earns $-128,080,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. PTC Therapeutics employs 511 workers across the globe.View Additional Information About PTC Therapeutics.

What is PTC Therapeutics' official website?

The official website for PTC Therapeutics is http://www.ptcbio.com/.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]


MarketBeat Community Rating for PTC Therapeutics (NASDAQ PTCT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  478 (Vote Outperform)
Underperform Votes:  470 (Vote Underperform)
Total Votes:  948
MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe PTCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel